Canaccord Genuity Maintains Buy on Quipt Home Medical, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Richard Close maintains a Buy rating on Quipt Home Medical (NASDAQ:QIPT) but lowers the price target from $8 to $6.

August 16, 2024 | 11:51 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity analyst Richard Close maintains a Buy rating on Quipt Home Medical but lowers the price target from $8 to $6.
The maintained Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates some caution about near-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100